William Michael Cunningham seeks permission to file amicus briefs.The Creative Investment Research CEO aims to file a brief in support of public interest.Cunningham has agreed to...
SEC chair Gary Gensler reported that the agency filed more than 700 actions.The regulator obtained judgments and orders summing to over $6.4 billion.Gensler remarked that they...
Amicus (NASDAQ:FOLD) Therapeutics FOLD shares rallied 6.4% in the last trading session to close at $10.13. This move can be attributable to notable volume with a higher number of...
Immunovant (NASDAQ:IMVT), Inc. IMVT reported a net loss of 35 cents per share in the second quarter of fiscal 2022 (ended Sep 30, 2021), wider than the Zacks Consensus Estimate of...
Amicus (NASDAQ:FOLD) Therapeutics, Inc. FOLD has announced its intent to spin-off its gene therapy business and form a next-generation genetic medicine company, Caritas...
Amicus Therapeutics, Inc. is a biotechnology company that is focused on discovering, developing, and delivering medicines for rare diseases. The Company's portfolio is Galafold (migalastat), which is the approved oral precision medicine for people living with Fabry disease. Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in patients with genetic variants. Migalastat is approved under the trade name Galafold in the United States, European Union, United Kingdom and Japan. Its biologics program in its pipeline is Amicus Therapeutics GAA (AT-GAA), which is a clinical-stage treatment paradigm for Pompe disease. Pompe disease is a lysosomal disorder (LD) from deficiency in an enzyme, GAA. AT-GAA consists of a uniquely engineered rhGAA enzyme, ATB200, or cipaglucosidase alfa, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with AT2221 (miglustat) that functions as an enzyme stabilizer.
|Average||15.400 (+20.031% Upside)|
|No. of Analysts||10|